Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.43 - $1.02
Previous CloseN/A
Volume29.92K
Average Volume (3M)127.98K
Market Cap
$52.78M
Enterprise Value$52.16M
Total Cash (Recent Filing)$725.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Mar 31, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding95,967,850
10 Day Avg. Volume166,631
30 Day Avg. Volume127,983
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)39.64
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit67.27
Enterprise Value/Ebitda-1.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
---
VolitionRX News
PremiumCompany Announcements
VolitionRx Limited Reports Strong 2024 Financial Results
PremiumCompany Announcements
VolitionRx Posts Strong Q3 Growth and Strategic Advances---
Ownership Overview
12.23% Insiders
1.35% Mutual Funds
16.91% Other Institutional Investors
68.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.43 and its highest was $1.02 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $52.78M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Mar 31, 2025 which is yesterday.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Mar 31, 2025. The company reported -$0.045 earnings per share for the quarter, beating the consensus estimate of -$0.055 by $0.01.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Overvalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.06.
How many shares outstanding does VolitionRX have?
VolitionRX has 95,967,850 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.045 in its last earnings report, beating expectations of -$0.055. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
---
VolitionRX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.34%
12-Months-Change
Fundamentals
Return on Equity
138.92%
Trailing 12-Months
Asset Growth
-29.71%
Trailing 12-Months
Company Description
VolitionRX
VolitionRX (VNRX) is a biotechnology company that focuses on developing blood-based diagnostic tests for various types of cancer and other diseases. The company is primarily engaged in the life sciences sector and aims to provide cost-effective, accessible tests that can be utilized in both human and veterinary diagnostics. VolitionRX's core technology revolves around its proprietary Nucleosomics platform, which identifies and measures nucleosomes in the bloodstream, potentially offering earlier detection and monitoring of disease.
---
VNRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with strong growth in sales and revenue, successful market expansion, and significant cost reductions. However, there are concerns about revenue predictability due to distributor stocking patterns, and the feline cancer test milestone remains pending.Read More>---
VNRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering VNRX
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-33.67%
reiterated a buy rating 11 months ago
Copying Ross Osborn's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -33.67% per trade.
---